Theriva™ Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced the dosing of the first patient in the VIRAGE2 Phase 2a clinical trial, a small proof-of-concept study evaluating more frequent repeated dosing of VCN-01 (zabilugene almadenorepvec) in first-line metastatic PDAC patients treated with standard-of-care gemcitabine/nab-paclitaxel chemotherapy (SoC;

The Foundation for Angelman Syndrome Therapeutics (FAST), the leading patient advocacy organization working to support the development of transformative treatment options for Angelman syndrome, today announced that it has entered into an agreement with Apertura Gene Therapy, a biotechnology company developing next-generation AAV capsids for delivering genetic medicines. Under the agreement, FAST may access TfR1 CapX™, Apertura's blood-brain barrier-crossing capsid technology, in inv

Alphamab Oncology (stock code: 9966.HK) today announced that the New Drug Application (NDA) for Anbenitamab (brand name: 恩尼妥®, KN026), a HER2 bispecific antibody independently developed by the Company, and co-developed with JMT-Bio Technology Co., Ltd., a wholly-owned subsidiary of CSPC Pharmaceutical Group Co., Ltd. (stock code: 1093.HK), in combination with CSPC’s Docetaxel for Injection (Albumin-bound) (HB1801), for the neoadjuvant treatment of early or locally advanced HER

Sanofi has received European Commission (EC) approval to extend the indication of its MenQuadfi (Meningococcal Group A, C, W and Y conjugate vaccine) to include infants from six weeks of age. The vaccine is approved to help protect against invasive meningococcal disease (IMD) caused by Neisseria meningitidis serogroups A, C, W and Y. MenQuadfi was previously authorised in the European Union for people aged 12 months and older. The approval follows a positive opinion from the Committee for Med

Verista, a leading provider of automation, compliance, and quality solutions for the life sciences industry, announced the acquisition of Integral Solutions. Based in Columbus, OH, Integral Solutions is a life sciences business and technology services firm that specializes in engineering and validation services worldwide. The acquisition enhances Verista’s capabilities in automation, engineering, project management, and validation, enabling the company to deliver further comprehensive s

Schrödinger, Inc. (Nasdaq: SDGR) today announced the launch of its early access version of Bunsen, its new agentic AI co-scientist that helps researchers understand scientific objectives, develop computational strategies, execute sophisticated molecular discovery workflows and interpret results. By combining AI with physics-based simulation, Bunsen allows researchers to apply their expertise at greater scale, enabling them to explore more scientific possibilities, prioritize the most pro

Idorsia Ltd (SIX: IDIA) has entered into an exclusive agreement with Jamjoom Pharmaceuticals Factory Co. (“Jamjoom Pharma”) for the distribution and commercialization of QUVIVIQ™ (daridorexant), Idorsia’s treatment for adults with insomnia, in Saudi Arabia and the Levant region. Benjamin Limal, President of Europe & International Markets for Idorsia, commented: “We are delighted to partner with Jamjoom Pharma, a leading pharmaceutical company

Gerresheimer, an innovative system and solution provider and global partner to the pharma, biotech, and cosmetic industries, has started operations at a new plant in Zhenjiang Dagang, China, for the production of glass primary pharmaceutical packaging. After approximately four years of construction, a state-of-the-art, energy-efficient building covering around 40,000 m² (60 mu) has been completed in the Zhenjiang Economic Development Zone in Jiangsu Province, fully meeting the stringent

BostonGene, the developer of the leading AI model for tumor and immune biology, today announced a strategic research partnership with Kyoto University, a research institution known for its groundbreaking advancements in medicine and science. The partnership supports a multicenter, Phase II clinical trial led by Dr. Manabu Muto of Kyoto University, evaluating the safety and efficacy of a combined therapeutic approach using immune checkpoint inhibitors (ICI) and photodynamic therapy (PDT) for p

JCR Pharmaceuticals Co., Ltd. (TSE 4552; “JCR”), a global specialty biopharmaceutical company dedicated to developing therapies for rare and genetic diseases, today announced that IZCARGOTM (pabinafusp alfa, or JR-141), a blood-brain barrierpenetrating enzyme replacement therapy (ERT) for Hunter syndrome developed using JCR’s proprietary J-Brain Cargo® technology, received marketing authorization in the United Arab Emirates (UAE). This marks the first marketing